ArticleJournal of ovarian research2025
Association between cytokines and progression-free survival in ovarian cancer following CRS/HIPEC treatment.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role of cytokines in ovarian cancer drug resistance.International journal of cancer · 2026Review
- Inflammatory milieu and role of epigenetic modifications in high-grade serous ovarian cancer.Clinical epigenetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe benefit of cytoreduction with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for epithelial ovarian cancer (EOC) remains uncertain. This study investigated the relationship between serum cytokines, particularly monocyte chemoattractant protein-1 (MCP-1), a key inflammatory mediator, and recurrence risk in EOC patients undergoing CRS/HIPEC.
methodsFrom January 2018 to January 2023, serum cytokine levels were analyzed in 34 EOC patients (17 primary, 17 recurrent) before and after CRS/HIPEC using MILLIPLEX Magnetic Bead Panels. Cox proportional hazards regression calculated adjusted hazard ratios (HRs) after controlling for clinical variables. Immunohistochemical (IHC) staining was performed on tissue microarrays from 19 patients.
resultsHigher 1-unit increment of MCP-1_Baseline were associated with increased recurrence risk within the first year post-CRS/HIPEC (HR: 1.010, 95% CI: 1.000-1.021). After one year, higher 1-unit increments of MCP-1_Post and MCP-1_Change were associated with increased recurrence risk. Lower IL-13 change and higher GROα change were associated with better progression-free survival (PFS) (p = 0.002 and p = 0.025, respectively). IHC analysis showed a trend towards worse PFS within the first year for patients with MCP-1 expression in tumor tissue (HR: 3.252, p = 0.264).
conclusionCytokines, particularly MCP-1, may help predict PFS following CRS/HIPEC in EOC patients and could inform postoperative treatment decisions. Further research is needed to confirm these findings and explore clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.